Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929223 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT04929223 is a Phase 1 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 542 participants, above the 174-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (211% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT04929223, a Phase 1 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Cetuximab
- DRUG Inavolisib
- DRUG Tiragolumab
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- cCare - Encinitas
- USC Norris Cancer Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford Cancer Center - Stanford
Connecticut
- Yale Cancer Center - New Haven
- Eastern Ct Hema/Onco Assoc - Norwich
Florida
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center - Tampa
New York
- New York Cancer & Blood Specialists - New Hyde Park - New Hyde Park
- New York Cancer and Blood Specialists-Central Park Hematology & Oncology - New York
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- University of Colorado Cancer Center - Aurora
Louisiana
- Mary Bird Perkins Cancer Ctr - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2030-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04929223
The ClinicalTrials.gov registry entry for NCT04929223 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (211% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04929223 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT04929223 about?
NCT04929223 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)". This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible ...
What is the current status of trial NCT04929223?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 542 participants. The study started on 2021-10-22. Estimated completion is 2030-08-31.
What conditions does trial NCT04929223 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04929223?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Cetuximab (DRUG), Inavolisib (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT04929223?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929223 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.